Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer

• Published in: Nature medicine Vol. 18; no. 2; pp. 221 - 223
• Main Authors: Montagut, Clara, Dalmases, Alba, Bellosillo, Beatriz, Crespo, Marta, Pairet, Silvia, Iglesias, Mar, Salido, Marta, Gallen, Manuel, Marsters, Scot, Tsai, Siao Ping, Minoche, André, Seshagiri, Somasekar, Serrano, Sergi, Himmelbauer, Heinz, Bellmunt, Joaquim, Rovira, Ana, Settleman, Jeff, Bosch, Francesc, Albanell, Joan
• Format: Journal Article
• Language: English
• Published: New York Nature Publishing Group US 01.02.2012; Nature Publishing Group
• Subjects: 692/699/67/1059/2326; 692/699/67/1504/1885; 692/699/67/1857; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Antineoplastic Agents - therapeutic use; Biomedical and Life Sciences; Biomedicine; brief-communication; Cancer Research; Cell Line, Tumor; Cetuximab; Colorectal cancer; Colorectal carcinoma; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - genetics; Development and progression; Drug resistance; Drug Resistance, Neoplasm - genetics; Epitopes - genetics; Humans; Infectious Diseases; Metabolic Diseases; Metastasis; Molecular Medicine; Mutation; Mutation, Missense - genetics; Neurons; Neurosciences; Quinazolines - therapeutic use; Receptor, Epidermal Growth Factor - genetics; Spain

By modeling acquired resistance to the EGFR antibody cetuximab in metastatic colorectal cancer, the authors identify a new mutation in the ectodomain of the receptor. The mutation is present in patient tumors after cetuximab therapy, confirming that it represents a clinically-relevant mechanism for...